Quantum BioPharma Ltd. (QNTM) - Total Liabilities
Based on the latest financial reports, Quantum BioPharma Ltd. (QNTM) has total liabilities worth $6.65 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore QNTM cash generation efficiency to assess how effectively this company generates cash.
Quantum BioPharma Ltd. - Total Liabilities Trend (2015–2024)
This chart illustrates how Quantum BioPharma Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Quantum BioPharma Ltd. to evaluate the company's liquid asset resilience ratio.
Quantum BioPharma Ltd. Competitors by Total Liabilities
The table below lists competitors of Quantum BioPharma Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ata Gayrimenkul Yatirim Ortakligi AS
IS:ATAGY
|
Turkey | TL149.18 Million |
|
Zivo Bioscience Inc
NASDAQ:ZIVO
|
USA | $3.85 Million |
|
Waja Konsortium Bhd
KLSE:0102
|
Malaysia | RM27.17 Million |
|
Huize Holding Ltd
NASDAQ:HUIZ
|
USA | $472.74 Million |
|
Financiere Marjos SA
PA:FINM
|
France | €1.17 Million |
|
Nextedia
PA:ALNXT
|
France | €22.49 Million |
|
Aco Group Bhd
KLSE:0218
|
Malaysia | RM63.90 Million |
|
Atalaya Mining Ltd
LSE:ATYM
|
UK | GBX178.66 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Quantum BioPharma Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Quantum BioPharma Ltd..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quantum BioPharma Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quantum BioPharma Ltd. (2015–2024)
The table below shows the annual total liabilities of Quantum BioPharma Ltd. from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.68 Million | +46.29% |
| 2023-12-31 | $4.57 Million | -41.98% |
| 2022-12-31 | $7.87 Million | -10.91% |
| 2021-12-31 | $8.83 Million | +56.08% |
| 2020-12-31 | $5.66 Million | -18.47% |
| 2019-12-31 | $6.94 Million | +442.08% |
| 2018-12-31 | $1.28 Million | +27.17% |
| 2017-12-31 | $1.01 Million | +1538.76% |
| 2016-12-31 | $61.43K | +1.49% |
| 2015-12-31 | $60.53K | -- |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in d… Read more